Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Roche, Biogen Idec Discontinue Development of Ocrelizumab for RA
May 31, 2010
- 2 Advanced Therapies Recommended for Combination with Insurance-Covered Therapies
May 31, 2010
- Suzuken: Operating Profits Down 14.5% Despite 4.9% Increase in Sales
May 31, 2010
- Insomnia Increases Risk of Diabetes: Prof. Watanabe
May 31, 2010
- Crestor Indicated in EU for Prevention of Major CV Events: AZ
May 31, 2010
- Toho HD: Sales Top \1 Trillion Benchmark
May 31, 2010
- Takeda President Yasuchika Hasegawa Elected JPMA President
May 31, 2010
- Settle Prices on a Product-by-Product Basis: Mr Matsutani
May 31, 2010
- JPMA Proposes Specific Measures for Growth Strategy
May 31, 2010
- Korosho Completes Hearings of Wholesalers on Changes in Business Practice
May 31, 2010
- Mr Shoda Elected President of Industry's FTC
May 31, 2010
- Pletaal No. 1 on HP Market, Ecard on GP Market
May 31, 2010
- Sales of Top-8 Domestic Companies Up 2.7%
May 31, 2010
- Shionogi Returns Moxifloxacin to Bayer Yakuhin
May 31, 2010
- Taisho: Sales of Ethical Drugs Up 4.8% to ¥99,590 Mil.
May 31, 2010
- Bufexamac to Be Withdrawn From EU Market
May 31, 2010
- Ono: Sales Down 0.4% Due to Competition with Generics
May 31, 2010
- Nippon Universal Renamed Zydus Pharma
May 31, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (1)
May 24, 2010
- Gaslon Accelerates Gastric Ulcer Healing after HP Infection
May 24, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…